Abstract: A novel antihypertensive drug, LCZ696 (Entrestoâ), has recently been introduced, which combines the action of an antagonist of the renin-angiotensin-aldosterone system (RAAS), effectively decreasing the blood pressure, with an inhibition of neprilysin, which is responsible for metabolizing natriuretic peptides exerting antihypertensive and antifibrotic effects. In this MiniReview, we describe the pharmacokinetics and pharmacodynamics, efficacy and side effects of the combined angiotensin receptor antagonist and neprilysin inhibitor LCZ696. We summarize the effect of LCZ696 treatment of patients suffering from hypertension and heart failure (HF) and further highlight the role of this new drug as a treatment option in the future. In the earlier stages of the treatment of patients with heart failure, LCZ696 was superior in lowering the blood pressure compared to olmesartan, while the effect on blood pressure at long-term treatment was comparable for the two drugs. The numbers of adverse effects were comparable. LCZ696 was superior to enalapril in reducing mortality, hospitalizations and HF symptoms. Adverse effects were reduced with a slower up-titrating regimen of 6 weeks. The current results are promising and suggest that LCZ696 will be a new candidate for first-line treatment of HF. However, it needs to be explored whether LCZ696 is safe in pregnant women, what are the effects of long-term LCZ696 treatment on survival and whether the antifibrotic effects can be of major benefit in, for example HF with preserved ejection fraction.
Hypertension (HT) is defined as a state when systolic blood pressure (SBP) and/or diastolic blood pressure (DBP) is elevated to an extent where it increases the risk of cardiovascular diseases (CVDs) [1] . In Europe, the threshold for HT is defined as a consultation blood pressure (BP) exceeding 140/ 90 mmHg and for diabetic patients exceeding 130/80 mmHg [2] . Some studies even show a correlation of growing risk of CVDs and increasing BP beginning at levels as low as 115/ 75 mmHg [3] .
When the BP rises above the limits for HT, epidemiological data show that the risk of intracranial haemorrhage, heart failure (HF), stroke and myocardial infarction (MI) greatly increases [4] .
In 2015, CVD was the leading cause of death accounting for 17.7 million deaths (31% of all deaths), with coronary heart disease and strokes being the major causes. It is estimated that an annual number of 7.5 million deaths are due to HT [5] . As WHO statistics do not distinguish between treated or non-treated HT, it remains unknown if some patients had been appropriately treated with antihypertensive drugs before the cardiovascular events.
In the effort to reduce the mortality from sequelae of HT, a considerable number of drugs have been developed. Of these drugs, beta-adrenoceptor antagonists (BAAs), calcium channel blockers, diuretics and blockers of the renin-angiotensin-aldosterone system (RAAS), such as renin inhibitors, angiotensin-converting enzyme inhibitors (ACEi), angiotensin II receptor type 1 (AT1R) blockers (ARBs), are the most used and valuable ones.
ARBs act on BP by preventing the binding of angiotensin II (ANG II) to the AT1R in the RAAS. Thereby, they inhibit ANG II-induced vasoconstriction, aldosterone release, stimulation of the sympathetic nervous system, and vascular and cardiac remodelling [6] . The RAAS is counteracted amongst others by natriuretic peptides (NPs), which on the one hand induce natriuresis, diuresis and vasodilation and, on the other hand, inhibit renin secretion via increases in cGMP [7] .
Recently, Novartis developed a dual action drug LCZ696 (brand name Entrestoâ), combining the neprilysin (NEP) inhibitor sacubitril and the ARB valsartan. It was postulated that this combination would retain the beneficial effects of increasing NPs and simultaneously antagonize the harmful effects of ANG II.
Pathophysiology of Hypertension and Heart Failure
Even though there is still a debate about the pathogenesis of HT, some common physiological changes have been observed in affected patients. Due to a thickening of the tunica media Author for correspondence: Daniela Grimm, Department of Biomedicine, Pharmacology, Aarhus University, Wilhelm Meyers All e 4, DK-8000 Aarhus C, Denmark (e-mail dgg@biomed.au.dk). musculature, the so-called vascular remodelling, the wall/lumen ratio increases [8] . Furthermore, an increase in activity of the sympathetic nervous system (SNS) leads to vasoconstriction and further reduces the lumen diameter [9] . These factors increase total peripheral resistance raising BP. An isolated increase in cardiac output is rarely observed.
If left untreated over a longer time, HT can lead to complications such as intracranial haemorrhages, left ventricular hypertrophy, HF, MI, thrombosis, angina pectoris and claudication intermittence [10] , with an augmented risk of comorbidities such as diabetes, earlier cardiovascular events, dyslipidaemia. The goal when initiating treatment is to decrease BP to below 140/90 mmHg and in diabetic patients below 130/80 mmHg by a combination of pharmacological and non-pharmacological interventions [4] .
Left ventricular hypertrophy can ultimately lead to HF with preserved ejection fraction (EF) (HFpEF) [11] . Another variant is HF with reduced EF (HFrEF). This form is defined by a reduction in the EF <40% due to a reduction in contractility, often post-MI or after long-term HT. HF is clinically classified by the New York Heart Association classification system (NYHA) ranging from class I, with patients having no symptoms or restrictions in their everyday life, to class IV not being able to do any physical work without discomfort and having symptoms at rest [11] .
The Renin-Angiotensin-Aldosterone System
The RAAS plays a central role in the control of the cardiovascular, renal and adrenal functions, which are important for body fluid and electrolyte balance, as well as arterial pressure. The endocrine axis is initiated by the regulated secretion of renin, which is synthesized and secreted by the juxtaglomerular cells in the kidney. Renin is capable of cleaving angiotensinogen (ANG) from the liver to angiotensin I (ANG I) that is further cleaved into ANG II by angiotensin-converting enzyme (ACE) in the lungs ( fig. 1 ) [12] [13] [14] . ACE also metabolizes the vasodilator bradykinin. Other routes of ANG II production have been described but are still not fully understood [15, 16] . ANG II is a multifunctional hormone and has several physiological effects concerned with fluid homeostasis initiated by the interaction of ANG II with two G proteincoupled receptors, angiotensin II receptor type 1 and type 2 (AT2R) [17, 18] . Two other receptors, the AT4R and the MAS Fig. 1 . Simplified overview of the metabolism and the effects of LCZ696. After ingestion, LCZ696 is converted into two active metabolites: valsartan and LBQ657. Valsartan has effect by blocking the AT1R, thereby inhibiting RAAS. LBQ657 inhibits the neutral endopeptidase, thereby inhibiting the degradation of the active NP. ANG, angiotensinogen; ANG I, Angiotensin I; ANG II, angiotensin II, ACE, angiotensin-converting enzyme; AT1R, angiotensin receptor 1; AT2R, angiotensin receptor 2; NP, natriuretic peptides; MasR, Mas receptor; NPR, natriuretic peptide receptor; RAAS, renin-angiotensin-aldosterone system; SNS, sympathetic nervous system. Parts of the figure were drawn by using pictures from Servier Medical Art. receptor, have also been identified [19] . The RAAS was described as a linear hormonal system for years, but the discovery of the ACE homologue ACE2, which forms angiotensin-(1-7) [ANG-(1-7)] from ANG II, and the MAS receptor (MasR) as an ANG-(1-7) receptor have added a second, counter-regulatory pathway [20, 21] . Angiotensin IV [Ang- (3) (4) (5) (6) (7) (8) binds to the AT4 receptor (AT4R) which is a transmembrane protein also known as insulin-regulated aminopeptidase and oxytocinase. Activation of AT4R is thought to be involved vasculo-and cerebro-protective effects as well as cognitive effects and renal metabolism, but knowledge of the AT4-receptor signaling pathway is incomplete [19] .
AT1R is present in high numbers in the musculature of the vessel wall causing vasoconstriction by increasing the intracellular calcium concentration and myofilament calcium sensitivity as well as growth [16, 22] . The activated AT1R also contributes to an acute increased release of noradrenaline from the SNS, thus further constricting the vessels. Apart from modulating the sympathetic out-flow, ANG II also exerts further acute effects on the central nervous system, such as the release of vasopressin and the inhibition of baroreflexes [23] . ANG II stimulates the secretion of aldosterone from the adrenal cortex leading to a sodium and fluid reabsorbing effect by increasing numbers of epithelial sodium channel in the collecting ducts, direct increase of sodium, fluid reabsorption in the proximal tubule and release of antidiuretic hormone from the neurohypophysis, which causes vasoconstriction and fluid reabsorption in the collecting ducts [24] as more long-term effects.
AT2R and MasR are the two receptors of the so-called protective arm of the RAAS. Long-term activation of AT2R has been described to be antiproliferative and antifibrotic [16, 24] , while the immediate effects of AT2R activation lead to vasodilatation, natriuresis and diuresis followed by BP lowering probably by stimulating renal production of cytokines and prostaglandins [25, 26] . New research indicates that the role of the AT2R is more complex, as an effect on vascular tone and decrease in BP by AT2R agonists (i.e. compound 21) are only revealed when an ARB is present. In addition, activation of AT2R appears to have long-term anti-inflammatory effects to inhibit remodelling of the arteries in hypertension, and to counteract atherosclerosis in diabetic animals [27] . Moreover, Leonhardt et al. [28] suggested that a heterodimerization of the AT2R and MasR can be found. The MasR is activated by ANG-(1-7) that can be formed from ANG I by neutral endopeptidase 24.11 or prolyl-endopeptidase or from ANG II via ACE2 [29, 30] and causes a vasodilatory effect through NO release [31] . Due to the described antifibrotic effects, ANG-(1-7) seems to exert opposite effects to those of ANG II by counteracting cell growth [32, 33] .
The Natriuretic Peptide (NP) System
The mammalian natriuretic peptide (NP) system is an endocrine system that maintains fluid and pressure homeostasis by modulating cardiac and renal function. Since the discovery in 1981, several types of NPs have been described: atrial (ANP) brain-(BNP, which was first identified in porcine brain extracts) and C-type natriuretic peptide (CNP). Whereas ANP and BNP are synthesized and secreted mainly from the cardiomyocytes in response to myocardial stretch [34, 35] , CNP is released from endothelial cells in response to physiological agonists [36] and by vascular injury [37] . NP levels are elevated in patients with heart failure (HF) and other cardiac diseases for restoring normal circulatory conditions [38] .
Their actions are modulated through guanylyl cyclasecoupled receptors A and B (NPR-A and NPR-B) and the more abundantly expressed G protein-linked NP-clearance receptor (NPR-C) ( fig. 1 ) [33, 34] . ANP and BNP (with lower affinity) bind selectively to NPR-A, while CNP binds to NPR-B and NPR-C and leads to activation of intracellular pathways [39] . By binding to NPR-C, natriuretic peptides are cleared from the bloodstream by endocytosis and intracellular inactivation [40, 41] . NPR-A and NPR-B induce the generation of the second messenger cyclic guanosine monophosphate (cGMP), which mediates via protein kinase G activation and serine/threonine kinases most of the physiological effects of the NPs including natriuretic and diuretic effects, as well as various cardioprotective and antihypertensive mechanisms such as vasodilation, a reduced SNS activity, inhibition of the RAAS (all more acute effects), induction of apoptosis and inhibition of fibrosis (long-term effects) [34, 38, 42] . Unlike ANP and BNP, CNP does not act as an endocrine hormone, but as a paracrine factor in the vasculature, mainly as a vasodilator and inhibitor of vascular cell proliferation [39, 43, 44] , although it is unclear whether CNP decreases blood pressure at physiological or pathological concentrations [45] .
Interestingly, in the central nervous system, the natriuretic peptides play a similar role as in the periphery, directly counteracting the effects of ANG II. Overall, central effects of natriuretic peptides include decreased salt and water intake, and inhibition of vasopressin, resulting in a reduction in body fluid and lowering of blood pressure [46] .
Neprilysin
Neprilysin (NEP) was first discovered in 1987 and was identified as an ANP-degrading zinc-dependent endopeptidase [47] . Over the years, it was found that not only ANP was a substrate of NEP, but also a multitude of other molecules was processed by it as well. In this context, the cardiorenal-related are the most important ones and they comprise ANP, BNP, CNP, angiotensins 1, 2, 3, 1-9, endothelin-1, endothelin-2, endothelin-3, adrenomedullin, and bradykinin [48] . NEP is expressed in epithelial cells, neutrophils and fibroblasts, and it has been located in many tissues, such as renal proximal tubules, the heart, the brain, lungs, blood vessels and thyroid [49] [50] [51] . Beside its membrane-bound form, NEP also has a soluble form, which can be found in the circulation, in the cerebrospinal fluid and in the urine [51, 52] .
By inhibiting NEP activity, the goal is to slow down NP breakdown, effectively increasing their beneficial vasodilatative action. However, it is important to keep in mind that NEP also degrades vasoconstrictors such as endothelin, which might limit the therapeutic efficacy of NEP inhibition.
LCZ696
LCZ696 is the first member in this new class of drugs and was reviewed recently [53] . The molecule consists of two active moieties in a 1:1 ratio, the well-documented ARB, valsartan and a NEPi pro-drug sacubitril (AHU337). In the literature, the new class is called angiotensin receptor/neprilysin inhibitor (ARNi), although angiotensin receptor antagonist/ neprilysin inhibitor would be more suitable. In accordance with the literature, ARNi will be used in this MiniReview.
LCZ696 Pharmacokinetic and Pharmacodynamic Properties
After oral ingestion, LCZ696 splits into the two units, AHU337 and valsartan. They are both rapidly absorbed. Once absorbed, AHU337 is transformed into the active NEPi, LBQ657, by enzymatic cleaving of an ethyl ester group primarily in the liver (AHU337 t 1/2 : 1.1-3.6 (hr) [54] ; 0.89-1.35 hr [53] ). This means that the active compounds valsartan and LBQ657 have an almost simultaneous and fast increase to maximum plasma concentrations. See table 1 for an overview of the pharmacokinetics. Valsartan is eliminated unchanged with urine or bile. LBQ657 is actively secreted into the urine via organic anion transporters 1 and 2 in the proximal tubule. The dose-exposure relationship for LBQ657 was found linear over the tested dose range (50-400 mg). The long t 1/2 of valsartan and LBQ657 makes LCZ696 suitable for once or twice a day administration. The recommended dose of LCZ696 is 100-400 mg daily [54, 55] .
Valsartan is an ARB. By having a much greater affinity for AT1R compared to AT2R, valsartan can inhibit the BP-raising and pro-fibrotic effects that are triggered by AT1R-mediated overproduction of reactive oxygen species causing hypertrophic cell growth, cell senescence, endothelial dysfunction, and cardiovascular and renal remodelling [56] , without interfering with the beneficial antihypertensive and cardioprotective effects of AT2R.
LBQ657 inhibits the neutral endopeptidase, an enzyme responsible for the degradation of NP. By preventing this process, the NP concentration increases and their cardioprotective and antihypertensive effects are enhanced ( fig. 1) [55] .
Clinical Trials with LCZ696
Currently, investigations on the efficacy, safety and tolerability of treatment with LCZ696 for patients with HT and HF are ongoing. In 2014 and 2015, phase 2 and 3 studies were completed. This MiniReview will focus on the latest completed studies with results and with study populations larger than 100 participants.
LCZ696 in Hypertension
A randomized, double-blinded, phase 3 study in Asia (China, Hong Kong, Taiwan, Thailand, Korea, Philippines and Singapore) investigated the efficacy of LCZ696 compared to the wellestablished ARB [57] , olmesartan, in 1435 Asian patients with mild to moderate HT [58] . The Asian participants were random- Mean sitting pulse pressure (msPP) was found significantly reduced for LCZ696 400 mg (p = 0.005) compared to olmesartan but only a tendency towards greater reduction for LCZ696 200 mg (p = 0.06). There was a significant difference in rates of controlled BP between LCZ696 400 mg and olmesartan 20 mg at 8.51% (95% CI: 2.18; 14.84%, p = 0.008) but not for LCZ696 200 mg (p = 0.15). There was no significant difference in rates of serious (SAE) and non-serious adverse events (AE). The findings of [58] are listed in table 2.
Another study comparing LCZ696 to olmesartan is NCT01876368 [59] . The study was a multi-centre study conducted in the United States, Russia, Spain, the Philippines, Argentina, Guatemala and Puerto Rico and included 375 participants. This double-blinded, randomized phase 3 study investigated the effects of 200 mg LCZ696 in patients with mild to moderate HT and non-responsive to olmesartan.
The study shows a significant difference in the effect to be 3.19 mmHg (95% CI: 1.65; 4.73 mmHg, p < 0.001) between LCZ696 and olmesartan in terms of mean 24-hr ambulatory SBP, and 1.92 mmHg 95% CI: 0.8; 3.0, p < 0.001) for mean 24-hr ambulatory DBP. There were no significant changes in pulse pressure, as found in NCT01785472 [58] .
When looking at the treatment success, the study revealed LCZ696 200 mg to be more efficient with a factor 1.45 (95% Table 1 . List of pharmacokinetics of the LCZ696 metabolites valsartan and sacubitril (AHU337).
Gu et al. [54] Han et al. [55] t In the elderly, the arterial wall stiffens and therefore SBP and pulse pressure are elevated. To evaluate the effects of LCZ696 on arterial stiffness, a multi-centre, randomized, double-blinded trial comparing LCZ696 to olmesartan measured the stiffness by a non-invasive, cuff-based device on the brachial artery [60] .
The study population consisted of 454 patients over 60 years and points towards a greater protective effect of LCZ696 compared to olmesartan regarding central aortic systolic pressure (CASP) reduction. The difference in CASP reductions was 3.66 mmHg (95% CI: 0.87; 6.45, p = 0.01) after 12 weeks. It seemed to diminish over time, becoming non-significant after 52 weeks (p = 0.27).
A reduction in central pulse pressure was significant after 12 weeks, too (2.45 mmHg (95% CI: 0.5; 4.4, p = 0.01) but was also non-significant after 52 weeks (p = 0.6).
The benefits of LCZ696 on peripheral BP also seem to be temporary. The data show a significant difference in reduction in SBP [6.27 mmHg (95%CI: 3.3; 9.2, p < 0.001)] and DBP [2.28 mmHg (95% CI: 0.7; 3.9, p < 0.006)] after 12 weeks. After 52 weeks of treatment, the beneficial effects of LCZ696 were statistically non-significant for both SBP (p = 0.10) and DBP (p = 1.18) compared to olmesartan.
LCZ696 was well tolerated with SAE occurring in 6.99% (5.78% in olmesartan, p = 0.62) and AE occurring in 31.88% (24.44% with olmesartan, p = 18.9). Of AE nasopharyngitis (p = 0.49), dizziness (p = 0.99), headache (p = 0.45) and cough (p < 0.04) were the most frequent. Only cough was significantly more frequent for LCZ696 compared to olmesartan.
LCZ696 in Heart Failure
The largest completed study so far is the PARADIGM-HF trial [61] . The study was a double-blinded, randomized, phase 3 trial including 8442 patients with HFrEF (NYHA class II-IV) and with an EF of <40%. After a run-in period of 3-6 weeks, participants were randomized to an ACEi, enalapril (10 mg twice daily) or LCZ696 (200 mg twice daily) group in a 1:1 ratio. After a 27-month median follow-up period, the trial was stopped early because predetermined results for effects were achieved. The study showed a decreased hazard ratio of 0.8 (95% CI: 0.73-0.87; p < 0.001) for deaths due to CVD or hospitalizations and a reduction in physical symptoms (p < 0.001) with LCZ696. The study concluded LCZ696 to be 'superior to enalapril in reducing risk of death and of hospitalization for heart failure'. [62] . McMurray et al. [63] later showed that LCZ696 caused a reduction in CVD mortality and hospitalization even as additional medication on top of BAA and mineralocorticoid receptor antagonists.
A phase 2 trial aimed to evaluate the safety and tolerability of LCZ696 for HF patients (NYHA class II-IV), NCT01922089 [64] . The study was conducted as a randomized, double-blind, multi-centre trial in the United States, Europe and Turkey. The 498 participants were randomized into two groups up-titrating to 200 mg LCZ696 twice daily in 3 or 6 weeks, respectively. The primary outcome was AE. See table 3 for most frequently reported AE.
LCZ696 seems to be well tolerated amongst the study population with 20.7-29.3% experiencing AE. No statistical significant difference in the prevalence of specific AE across the different up-titrating regimes was found although a significant difference in the total number of AE was found. Participants in the 3-week up-titrating group had increased risk of 1.41 (95% CI: 1.04; 1.93, p = 0.02).
As seen in table 3, the prevalence of angiooedema is very low. This is a valuable benefit compared to treatment with ACEi. During an ACEi therapy, the vasodilating bradykinin accumulates ( fig. 1) .
A second outcome measure was the treatment success defined as: '. . .the number of participants who achieved and maintained 
Discussion and Conclusion
Three studies evaluated the effect of LCZ696 compared to olmesartan in the treatment of HT in Asian patients [58] , in patients with essential HT not adequately responsive to olmesartan [59] and elderly patients [60] . They all found LCZ696 There is no statistical difference in the prevalence of specific AE between the two up-titrating regimens. The total number of AE was significantly higher in the 3-week up-titrating group 1.41 (1.04; 1.93; p: 0.02). The tolerability of the 6-week regimen was found borderline non-significantly improved compared to 3-week regimen [0.92 (0.85; 1.01; p = 0.07)] Conclusion LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure LCZ696 is well tolerated amongst the study population. 6-week up-titrating regimens is superior to 3-week up-titrating regimen in regard to AEs and tolerability to be superior in lowering the peripheral BP or CASP, although the effect seems to become non-significant over time [60] . Furthermore, the studies all point towards the same level of tolerability and AE for LCZ696 as for olmesartan. See  table 4 for an overview of HT trials. In the treatment of HF, two studies were reviewed. The PARADIGM-HF trial concluded LCZ696 to be superior to enalapril in reducing mortality, hospitalization and symptoms of HF [61, 62] . LCZ696 was putatively evaluated to be superior to placebo [61] . Another trial evaluated the tolerability and AE associated with different up-titrating regimes. They found a 6-week up-titrating regimen to have less AE and a borderline higher success rate compared to a 3-week up-titrating regimen [64] . See table 5 for an overview of HF trials.
The results of the unpublished study do not include demographics other than age and gender [58] [59] [60] 64] . Therefore, a great number of factors could confound the effects including body mass index, earlier cardiovascular events, dyslipidaemia, smoking status, alcohol habits, diabetes, ethnicity, etc. If demographics are known, they should be included when the results are published. By randomizing the study population, this problem is limited.
Another problem is the fact that there are no placebo controls for any of the mentioned studies [58] [59] [60] [61] 64] , which makes it difficult to draw any conclusions from the numbers. Because there is no placebo group, the efficacy of the drugs will appear artificially high as placebo has a documented effect. The same is the case for AE, which will also appear artificially high as the background prevalence is not subtracted. Therefore, the AE attributed to LCZ696 can only be compared to the AE profile of similar drugs.
To date, not a single completed study registered on clinicaltrials.gov has been conducted or founded by others than Novartis Pharmaceuticals. This is a problem as the sponsor has a major economic benefit from positive results. This might therefore create a bias amongst the investigators. By using the double-blinded study design, this potential bias is diminished. Nevertheless, future studies by independent centres will be necessary and helpful to validate these findings.
NP and the RAAS exert an important control of BP and body fluid homeostasis. LCZ696 is a first-in-class angiotensin receptor antagonist/neprilysin inhibitor. It has effect by limiting the BP-elevating effects of RAAS and enhancing the BPreducing effect of NP, besides having antifibrotic effect. The current trials all found a remarkable short-term effect on blood pressure in hypertensive and heart failure patients. LCZ696 has a significantly greater effect on BP, hospitalization and mortality compared to enalapril and olmesartan. However, a study, NCT01692301 [59] , showed a reduced benefit with long-term use. The effects with long-term use should therefore be further investigated.
LCZ696 is generally well tolerated. The most common side effects are mild and rare. Further investigations will be needed to evaluate how the treatment will affect other patient groups, for example black people, pregnant women, patients with HFpEF, patients with severe HT (>180 mmHg) and patients with comorbidities, for example diabetes.
At the moment, a lot of trials are under way including phase 4 trials with 1000 participants.
Outlook
LCZ696 shows a great potential in the treatment of HF. If future studies will find a maintained long-term effect, compared to the current treatment options, LCZ696 may become a new first-line drug for the treatment of HFrEF. The actual price of the drug has to be discussed. The treatment with Entresto (400 mg) will cost 48.42 DKK a day [65] . In comparison, equivalent doses of enalapril (20 mg) and valsartan (160 mg) will cost 0.27 DKK [65] and 1.2 DKK [65] , respectively, per day. Therefore, the possible economic impact will need to be closely considered.
Furthermore, some aspects of LCZ696 are still open for future investigations; for example, chronic kidney disease and diabetes are both associated with vascular and organ fibrosis, and therefore, it would be interesting to clarify whether LCZ696 treatment alone or in combination with mineralocorticoid receptor antagonists can prevent and/or reverse the fibrosis in these conditions.
